Switching of anti-VEGF medications to biosimilar alternatives
Information to support safe and effective switching to biosimilar anti-VEGF treatments. Designed for medical retina teams, service managers and pharmacy colleagues, covering consent, prescribing, cost considerations and pathway planning.